Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC reduced its position in Arvinas, Inc. (NASDAQ:ARVN – Get Rating) by 2.1% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 170,943 shares of the company’s stock after selling 3,586 shares during the quarter. Nuveen Asset Management LLC owned about 0.32% of Arvinas worth $7,605,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of ARVN. Raymond James & Associates grew its stake in shares of Arvinas by 21.3% during the 1st quarter. Raymond James & Associates now owns 6,686 shares of the company’s stock worth $450,000 after purchasing an additional 1,172 shares during the period. MetLife Investment Management LLC grew its stake in shares of Arvinas by 55.4% during the 1st quarter. MetLife Investment Management LLC now owns 25,350 shares of the company’s stock worth $1,706,000 after purchasing an additional 9,039 shares during the period. Rhumbline Advisers grew its stake in shares of Arvinas by 3.1% during the 1st quarter. Rhumbline Advisers now owns 49,324 shares of the company’s stock worth $3,320,000 after purchasing an additional 1,479 shares during the period. BlackRock Inc. grew its stake in shares of Arvinas by 0.6% during the 1st quarter. BlackRock Inc. now owns 3,525,259 shares of the company’s stock worth $237,251,000 after purchasing an additional 19,519 shares during the period. Finally, Great West Life Assurance Co. Can grew its stake in shares of Arvinas by 743.7% during the 1st quarter. Great West Life Assurance Co. Can now owns 17,786 shares of the company’s stock worth $1,271,000 after purchasing an additional 15,678 shares during the period. 92.03% of the stock is owned by institutional investors and hedge funds.

Arvinas Stock Down 6.0 %

Shares of NASDAQ:ARVN opened at $27.03 on Friday. Arvinas, Inc. has a 52-week low of $26.68 and a 52-week high of $75.39. The company has a 50 day moving average of $32.80 and a two-hundred day moving average of $39.41. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -5.08 and a beta of 1.78.

Arvinas (NASDAQ:ARVN – Get Rating) last issued its quarterly earnings data on Thursday, February 23rd. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.46). The firm had revenue of $38.00 million during the quarter, compared to analyst estimates of $35.32 million. Arvinas had a negative net margin of 228.19% and a negative return on equity of 43.79%. The firm’s revenue was up 32.4% compared to the same quarter last year. During the same period last year, the business earned ($1.00) EPS. On average, equities analysts anticipate that Arvinas, Inc. will post -6.01 earnings per share for the current year.

Analyst Ratings Changes

ARVN has been the topic of several recent research reports. Guggenheim lowered shares of Arvinas from a “buy” rating to a “neutral” rating in a research report on Thursday, January 12th. Morgan Stanley decreased their price objective on shares of Arvinas from $57.00 to $36.00 and set an “equal weight” rating on the stock in a research report on Monday, February 27th. HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Arvinas in a research report on Friday, February 24th. Oppenheimer decreased their price objective on shares of Arvinas from $102.00 to $95.00 in a research report on Tuesday, January 10th. Finally, Barclays decreased their price objective on shares of Arvinas from $90.00 to $70.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 23rd. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Arvinas has an average rating of “Moderate Buy” and an average target price of $68.44.

Insider Activity

In related news, CEO John G. Houston sold 5,878 shares of the firm’s stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $29.53, for a total transaction of $173,577.34. Following the transaction, the chief executive officer now directly owns 917,427 shares in the company, valued at $27,091,619.31. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Ian Taylor sold 1,051 shares of the firm’s stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $29.53, for a total transaction of $31,036.03. Following the transaction, the insider now directly owns 101,721 shares in the company, valued at $3,003,821.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John G. Houston sold 5,878 shares of the firm’s stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $29.53, for a total value of $173,577.34. Following the transaction, the chief executive officer now owns 917,427 shares in the company, valued at $27,091,619.31. The disclosure for this sale can be found here. In the last three months, insiders sold 8,674 shares of company stock worth $256,143. 2.78% of the stock is currently owned by insiders.

Arvinas Company Profile

(Get Rating)

Arvinas, Inc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.